Acologix Presents Data on Cartilage Regeneration by AC-100 at the 56th Annual Meeting of the Orthopaedic Research Society
HAYWARD, Calif., March 6 /PRNewswire/ -- Acologix, Inc., a
privately held biopharmaceutical company, today announced the
results of its latest preclinical study demonstrating that AC-100,
its therapeutic product candidate derived from an endogenous human
protein, promotes cartilage regeneration in a large animal model.
The data will be presented by Dr. David M. Rosen on March 6, 2010
at the 56th annual meeting of the ORS (Orthopaedic Research
Society) in New Orleans, LA.
The effects of AC-100 on cartilage regeneration were evaluated
in goats with standardized defects in knee cartilage. Four weekly
intra-articular injections of AC-100 or placebo were administered.
Quantity and quality of cartilage regeneration were evaluated after
six months.
AC-100 dose dependently promoted cartilage repair compared to
placebo. Furthermore, the new cartilage formed in response to
AC-100 was mature, normal hyaline cartilage as assessed by several
histological staining methods. Similar to previous studies, AC-100
exhibited a favorable safety profile in this study, with no
inflammatory response.
"These results showing normal cartilage regeneration with AC-100
strongly support our excitement for this program, and we are
looking forward to initiating clinical trials in osteoarthritis and
traumatic cartilage injury," said Dr. Dawn McGuire, Chief Medical
Officer of Acologix. "The previously demonstrated ability of AC-100
to promote regeneration of underlying damaged bone makes the use of
AC-100 a unique approach for repair and regeneration of hard tissue
in OA, RA, and traumatic injury."
Acologix, Inc.
Acologix, Inc. a privately held biopharmaceutical company, is
developing and commercializing novel biopharmaceuticals targeting
osteo-renal indications, including the complications with chronic
kidney disease and dialysis, bone and cartilage repair and
regeneration, and general dental and oral care. The company's most
advanced program, AC-820 is at the Phase 3 stage in the U.S. and
was approved for sale in Japan in January of 2009 for the treatment
of uremic pruritus in dialysis patients. The second program,
AC-100, a hard tissue growth promoting molecule, has been studied
in two Phase II clinical studies and demonstrated high safety
profile and selective hard tissue formation activities in dental
restoration procedures. Further studies have revealed that AC-100
also selectively promotes bone and cartilage repair and
regeneration. Acologix is also developing AC-200 (Phosphatonin) to
treat bone loss associated with chronic kidney disease. For more
information, go to www.acologix.com.
Abstract Number 974 "AC-100 Promotes Cartilage Defect Repair in
Vivo and Chondrocyte Differentiation and Function in Vitro" by
Catherine Middleton-Hardie, Ph.D. and David Rosen, Ph.D. of
Acologix, Harold Aberman, D.V.M., Tim Simon, Ph.D. of Applied
Biological Concepts, and Tamara Alliston, Ph.D. and Ashton
Mortazavi, Ph.D. from the Department of Orthopedic Surgery,
University of California, San Francisco. Presented as Poster #974
by Dr. David Rosen on Saturday, March 6, 2010, at the 56th Annual
Meeting of the Orthopedic Research Society in New Orleans,
LA.
This press release contains "forward-looking" statements. These
statements involve risks and uncertainties, which may cause results
to differ materially from those set forth in the statements. The
forward-looking statements include statements regarding product
development and cannot be guaranteed. Acologix undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise. Forward-looking statements in this press release should
be evaluated together with the many uncertainties that affect
Acologix' business.
Source: Acologix, Inc.
CONTACT: Yoshi Kumagai, President and CEO of Acologix,
+1-510-512-7200,
Fax, +1-510-786-1116, ir-usa@acologix.com
Web Site: http://www.acologix.com/
Posted: March 2010
